{"eventGroups":[{"description":"GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen\n\nGDPT regimen: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.","id":"EG000","otherNumAffected":21,"otherNumAtRisk":52,"seriousNumAffected":23,"seriousNumAtRisk":52,"title":"GDPT Regimen"},{"description":"CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen\n\nCHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.","id":"EG001","otherNumAffected":19,"otherNumAtRisk":51,"seriousNumAffected":21,"seriousNumAtRisk":51,"title":"CHOP Regimen"}],"frequencyThreshold":"0","otherEvents":[{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":52},{"groupId":"EG001","numAffected":19,"numAtRisk":51}],"term":"digestive tract toxicity"}],"seriousEvents":[{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":52},{"groupId":"EG001","numAffected":21,"numAtRisk":51}],"term":"Grade3/4 myelosuppression"}]}